通策醫療(600763.SH):參股基金壹號基金進入清算期
格隆匯6月24日丨通策醫療(600763.SH)公佈,今日收到參股基金浙江通策壹號投資合夥企業(有限合夥)(簡稱“壹號基金”、“參股基金”)進入清算期的通知。壹號基金設立後,所有投資已全部完成,但截至最新,旗下項目發生重大訴訟,且壹號基金合夥人因相關事項無法達成一致,導致壹號基金議事程序無法進行;工商備案的原壹號基金經營期限已於2024年9月12日到期,經與各合夥人口頭溝通,無法就壹號基金的經營期限作出延長。壹號基金爲公司參股的基金,清算不會影響公司現有業務,不會影響當期損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.